ROBERT SEWARD: Open Payments
NPI 1063402600 · RICHMOND, VA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,405 in 131 payments from 20 companies in 2025. Trend: 2023 $2,420 · 2024 $2,735 · 2025 $2,405
Food & beverage: $2,405
| Company | Payments | Amount |
|---|---|---|
| Vanda Pharmaceuticals Inc. | 18 | $373 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 20 | $307 |
| Neurocrine BioSciences, Inc. | 13 | $307 |
| ABBVIE INC. | 21 | $230 |
| E.R. Squibb & Sons, L.L.C. | 9 | $175 |
| Axsome Therapeutics, Inc. | 6 | $136 |
| Janssen Pharmaceuticals, Inc | 4 | $120 |
| Alkermes, Inc. | 5 | $109 |
| Lundbeck LLC | 5 | $101 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $93 |
Products named: CAPLYTA, INGREZZA, FANAPT, VRAYLAR, COBENFY, Auvelity, REXULTI, ARISTADA.
Industry payments across VA — which companies pay providers there.
